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Background: Efforts to improve patients’ understanding of their own medical treatments or research in which they
are involved are progressing, especially with regard to informed consent procedures. We aimed to design a multisource
informed consent procedure that is easily adaptable to both clinical and research applications, and to evaluate its
effectiveness in terms of understanding and awareness, even in less educated patients.
Methods: We designed a multisource informed consent procedure for patients’ enrolment in a Cancer Institute
Biobank (CRO-Biobank). From October 2009 to July 2011, a total of 550 cancer patients admitted to the Centro di
Riferimento Oncologico IRCCS Aviano, who agreed to contribute to its biobank, were consecutively enrolled. Participants
were asked to answer a self-administered questionnaire aim at exploring their understanding of biobanks and their
needs for information on this topic, before and after study participation. Chi-square tests were performed on the
questionnaire answers, according to gender or education.
Results: Of the 430 patients who returned the questionnaire, only 36.5% knew what a biobank was before participating
in the study. Patients with less formal education were less informed by some sources (the Internet, newspapers,
magazines, and our Institute). The final assessment test, taken after the multisource informed consent procedure,
showed more than 95% correct answers. The information received was judged to be very or fairly understandable in
almost all cases. More than 95% of patients were aware of participating in a biobank project, and gave helping cancer
research (67.5%), moral obligation, and supporting cancer care as main reasons for their involvement.
Conclusions: Our multisource informed consent information system allowed a high rate of understanding and
awareness of study participation, even among less-educated participants, and could be an effective and easy-to-apply
model for others to consider to contribute to a well-informed decision making process in several fields, from clinical
practice to research.
Further studies are needed to explore the effects on the study comprehension by each source of information, and by
other sources suggested by participants in the questionnaire.
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Most recent studies aimed at improving patients’ under-
standing of the research or medical treatment in which
they are involved concern comprehension of informed
consent [1], rather than the participants’ awareness, mo-
tivation, or willingness [2]. These latter topics are little
studied at present. Although patients’ involvement
should be conscious and free from pressure or condi-
tioning, the information phase is usually limited to the
patient signing an informed consent form. However, a
patient’s informed consent should also imply that the pa-
tient has received complete information and fully under-
stands its meaning, so that conscious decisions can be
taken [3-5].
However, when an information can be considered
“complete”? No strong consensus exists as to adequate
type and amount of information patients require, espe-
cially in the context of clinical research [6]. Signed in-
formed consent forms can merely be considered as
documentary evidence that patients have consented to
participate, and had received the required information—
but not that they thoroughly understood the given
information.
The ethically valid process of informed consent in-
cludes indeed five elements: voluntarism, capacity, dis-
closure, understanding, and decision [6]. A review by
Falagas and colleagues on informed consent process in
clinical research showed that, in half of 30 considered
studies, participants did not clearly understand the aim
of clinical trials, or the fact that participation was volun-
tary, and that they could withdraw at any time. They
were also unaware of the risks and benefits of treatment
and the process of randomization. Moreover, sufficient
understanding seems not to be directly attributable to
the type of information provided but rather to the use of
plain oral and written language, and to the time practi-
tioners dedicated to clarifying any misunderstandings [7].
These topics raise nowadays an increased interest also
in the field of biobanks [8]. Differently from what is
sometimes thought, interventions to promote understand-
ing of the aims and methods of biobanks, and enhanced
awareness of their research applications, reportedly en-
hances individual willingness to participate in biobank
collection [8-10]. Biobanks can be defined as “non-profit
service facilities aimed at the collection and storage of hu-
man biological material to be used for diagnosis, biodiver-
sity studies, and research” [11]. Cancer biobanks are of
particular interest to both academic and industrial investi-
gators; and the availability of large numbers of well-
prepared samples is representative of the diversity and
heterogeneity observed in tumour biology [12]. Without
the contribution of patients, who provide their samples
and associated information (therapies and outcome), im-
provement of treatments for cancer and other diseasescould be severely delayed. Despite the great importance of
patients’ connection with biobanks, they are often not
aware of their fundamental role in medical research ad-
vance [13].
As with research projects and medical treatments, par-
ticipants in biobanks should be informed about the pur-
pose of their intervention, ways of execution, and related
benefits and risks [14]. Unfortunately, often this is not
the case: in one study, none of the participants was aware
that he/she had samples stored in a DNA bank [15].
In 2006, the Centro di Riferimento Oncologico (CRO),
National Cancer Institute, Aviano, Italy, established a
biobank (CRO-Biobank) for cancer research purposes. It
is a long-term source of human biological samples and
associated information, collected at diagnosis and at
consecutive therapeutic stages, in compliance with qual-
ity standards. Because the sole informed consent form,
accompanied by technical information, was often unclear
to patients [16,17], even in a simplified version [1], we
implemented a multisource information procedure. The
main purpose of this study was to evaluate the effective-
ness of this approach through the use of a self-
administered questionnaire. We compared patients’
knowledge before and after receiving information, and
investigated the effect of the information sources: en-
hanced informed consent form, physician, biobank nurse
or biologist, brochures, posters, the internet, television,
etc. To find out how to enhance involvement and aware-
ness, we also explored how patients expressed the need
for further information, the sources they preferred, and
the motivations that led them to contribute to the re-
search. The questionnaire also investigated patients’ per-
ception of the treatment of their individual and privacy
rights to understand whether they felt respected as re-
search stakeholders, and to reinforce their awareness
and trust in the CRO-Biobank.
Methods
From October 2009 to July 2011, 550 patients who had
been admitted to the Centro di Riferimento Oncologico,
IRCCS Aviano (CRO), National Cancer Institute, in
North–East of Italy agreed to contribute to its biobank
(CRO-Biobank) and were consecutively enrolled; 430
participants (78.2% of total; 86 men and 344 women;
median age 56, age range 18–84) returned the filled-in
questionnaire. Sample size was determined by number
of cases presented during the study period. Eligibility cri-
teria were: age ≥ 18 years, Italian speaking, and having
histologically confirmed cancers or precancerous lesions.
Patients’ main reason for non-participation was being
too debilitated to fill out the form on hospital discharge.
The Institutional Ethics Committee (Comitato Etico
Indipendente, Centro di Riferimento Oncologico, IRCCS,
Aviano, Italy) approved the CRO-Biobank project. All
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pate. Participation involved collection of blood and, in
case of surgery, tissue samples donated to the biobank
for cancer research purposes. The CRO-Biobank de-
signed a multiple-source patient information system
(Figure 1). First, an enhanced informed consent form
was designed as a readable, easy-to-fill model with a
special attention to language, layout, organization of the
information sequence, and typography. In the visit be-
fore starting treatment, physicians explained the contents
of the form to patients, and collected the informed con-
sent after giving all details of the CRO biobank purposes
and the implications of the enrolment. Later, before collec-
tion of biological material, a biobank nurse (or a biobank
biologist) gave further information in plain language, and
answered any questions that might have arisen. Informa-
tion included details on the purpose and activity of the
biobank, on the informed consent form (such as the right
to withdraw), and the existence of a dedicated phone line.
The interview was performed contextually with the collec-
tion of anamnestic data and required about 15 minutes.
Patients were also each given a brochure with a take-
home message, written in simple terms, and containing
figures and schemes [see Additional file 1]. The informa-
tional material can be found in various places around
the Institute (i.e., brochures, posters, and the InstituteFigure 1 Schematization of the multisource informed consent assessm
information are shown in light blue; assessment tools are shown in orange
Lower panel: Other information sources provided by the Institute.magazine, available in display cases or stands), on the in-
stitutional website (http://www.cro.sanita.fvg.it/ricerca/set_
biobanca.htm), and through a dedicated phone line.
During their hospital stay (for surgery, chemotherapy,
or stem cell autologous transplantation) participants
were each asked to take a written, self-administered
questionnaire to assess their information levels and
needs, aimed at investigating the effectiveness of our in-
formation system. The time elapsed between consent
and response to the questionnaire was between 5 and
30 days. The questionnaire investigated patients’ know-
ledge of biobanks before and after participating in the
study, the perceived quality of our informational methods,
and how well the patients felt their privacy had been
respected. It also included some demographic data and a
final assessment test to measure the understanding of the
form [see Additional file 2]. The questionnaire was vali-
dated prior to administration by administering it to a sam-
ple of 20 subjects and evaluating its understanding,
validity and reproducibility. A few days later, we
interviewed those subjects asking them the same ques-
tions to see if the answers were comparable to those
marked in the questionnaire, and inquiring whether they
had any difficulties in filling in answers.
Demographic characteristics (age, gender, education,
and marital status), in addition to the admission ward,ent procedure performed by the CRO-Biobank. Sources of
. Main panel: Informed consent procedure undergone by patients.
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divided into three groups: ≤ 50, 51–60, and ≥ 60 years.
Participants were initially grouped according to gender;
simple frequencies of demographic data were then
assessed.
Patients were later divided into three groups by educa-
tion level (those with elementary school, middle school,
or high school/university education) to see whether for-
mal education affected comprehension of information
from different sources, as analyzed with a χ2test. Three
participants were excluded from these analyses because
of missing education data. Statistical analyses were
performed using SAS software, version 9.1 (SAS Insti-
tute, Inc., Cary, NC).
Results
Table 1 shows the distribution of demographical charac-
teristics of participants according to gender. The study
had more female patients than male patients, prevalently
because of the higher contribution of the Gynaecology
Oncology Surgery Unit. Nevertheless, no differences be-
tween variables were observed except for the Oncology
Unit ward.
Table 2 reports patients’ answers about their know-
ledge of biobanks before entering the study. About oneTable 1 Distribution of personal characteristics of the 430 pa
Gend














Elementary school 19 (22.1)
Middle school 27 (31.4)
High school/University 40 (46.5)
Oncology unit
General oncology—surgery 59 (68.6)
Gynaecology oncology—surgery –
Medical oncology 19 (22.1)
Other 8 (9.3)
aNumbers do not add up to the total because of missing values.third of patients (36.5%) were aware of the existence of
biobanks. Of these patients, 25.8% had attended elemen-
tary school, 36.2% middle school, and 41.9% high school
or college; 30.7% derived information mainly from CRO
sources (website, posters, phone line, brochures, etc.),
21.3% by television, and 17.6% by newspapers or maga-
zines. Three sources of information (the Internet, CRO,
and newspapers/magazines) shows statistically signifi-
cant differences between patients who attended elemen-
tary school (less informed by these sources) and more
educated patients. Information found on television or
obtained from other hospitals did not differ between
groups.
Table 3 shows participants’ perception of the quality of
information received by the CRO-Biobank during enrol-
ment, according to education. Most patients, 93.4%, had
read the brochure, 83.6% reported being informed by a
physician, and 89.2% by a biobank nurse or biologist.
The information was evaluated as “very understandable”
by the majority of participants (brochure: 61.4%; nurse/
biologist: 61.7%; physician: 50.5%). More highly educated
participants rated the sources of information as signifi-
cantly clearer than did less educated participants. Over-
all, 53.8% patients rated the enhanced informed consent
form to be “fairly understandable”, 44.9% as “veryrticipants, divided by gender; 2009–2011
er
Female (n = 344) Totala (n =430) P value
N (%) N (%)
331 (96.2) 412 (95.8)
13 (3.8) 18 (4.2) 0.40
123 (35.8) 148 (34.5)
110 (32.0) 131 (30.5)
111 (32.3) 150 (35.0) 0.06
47 (13.7) 55 (12.9)
247 (72.2) 314 (73.4)
48 (14.0) 59 (13.8) 0.49
78 (22.9) 97 (22.7)
100 (29.3) 127 (29.7)
163 (47.8) 203 (47.5) 0.93
57 (16.6) 116 (27.0)
191 (55.5) 191 (44.4)
17 (4.9) 36 (8.4)
79 (23.0) 87 (20.2) < 0.001
Table 2 Distribution of answers given by patients to the questionnaire investigating their knowledge about biobanks









N (%) N (%) N (%) N (%)
Were you aware of the existence of biobanks?
No 72 (74.2) 81 (63.8) 118 (58.1) 271 (63.5)
Yes 25 (25.8) 46 (36.2) 85 (41.9) 156 (36.5) 0.03
What was the source of information?
Television
No 80 (82.5) 97 (76.4) 159 (78.3) 336 (78.7)
Yes 17 (17.5) 30 (23.6) 44 (21.7) 92 (21.3) 0.54
Newspapers/magazines
No 91 (93.8) 104 (81.9) 157 (77.3) 352 (82.4)
Yes 6 (6.2) 23 (18.1) 46 (22.7) 75 (17.6) 0.002
Internet
No 96 (99.0) 120 (94.5) 183 (90.2) 399 (93.4)
Yes 1 (1.0) 7 (5.5) 20 (9.9) 28 (6.6) 0.01
CROb
No 79 (81.4) 89 (70.1) 128 (63.1) 296 (69.3)
Yes 18 (18.6) 38 (29.9) 75 (37.0) 131 (30.7) 0.005
Other hospitals
No 93 (95.9) 125 (98.4) 189 (93.1) 407 (95.3)
Yes 4 (4.1) 2 (1.57) 14 (6.9) 20 (4.7) 0.08
a Numbers do not add up to the total because of missing values.
b Centro di Riferimento Oncologico, IRCCS, Aviano.
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able”. Also, 56.1% of participants wished to receive more
information on biobanks; 20.1% wished to be informed
by multiple sources, 18.5% by CRO, 11.2% by websites
(mostly patients with high school or university educa-
tions), and 4.9% by their general practitioner (mostly less
educated patients) (data not shown).
Table 4 shows distribution of answers regarding partic-
ipants’ knowledge of biobanks after enrolment, ac-
cording to education. The large majority of patients
(95.5%) were aware of their participation in the CRO-
Biobank (as all participants donated biological samples to
our biobank, the question: “Did you donate biological ma-
terial to CRO-Biobank?” intended to investigate whether
they were aware of their participation). We also performed
a trend test confirming that more educated participants
were more aware of their participation (P = 0.02). The
questions on their knowledge of biobanks were answered
correctly by more than 95% of patients, with no differ-
ences observed according to education.
The reasons for participating in the CRO-Biobank
(open question) were grouped into three main categories:
to help cancer research (67.5%), to support care/for moral
obligation (17.6%), and other (14.0%) (data not shown).Over 98% of patients answered that the interview settings
ensured their privacy and that the collection of biological
samples was respectfully conducted (data not shown).
Discussion
Active involvement of patients in the health sector is
growing [18,19]. Patient involvement affects procedures
and decisions regarding health policy [20], treatment
[21], research [18,22], health technology assessments
[23], genetic testing [24], and scientific advisory pro-
cesses [19]. Patient involvement is thought to make
health systems more user-friendly and information more
accessible. Patient empowerment also involves respect-
ing their rights and voices [25]. For these reasons, in-
formed consent considerations cannot be ignored.
Informed consent represents a very fundamental tool to
achieve these goals; development of an efficient proced-
ure that respects these principles is critical.
As per law and ethics, in many countries, physicians
must collect informed consent from each patient or pa-
tient’s representative (e.g. parent or guardian) before en-
rolment in a study or initiating treatment [3,4]. This rule
also applies to biobanks, as the biological material they
collect is for scientific research purposes. Although the
Table 3 Distribution of answers given by 430 patients regarding their perception of quality of information about









N (%) N (%) N (%) N (%)
What was the source of information?
Brochure
No 6 (6.4) 10 (8.3) 11 (5.6) 27 (6.6)
Yes 88 (93.6) 110 (91.7) 186 (94.4) 384 (93.4) 0.63
How would you rate it?
Unclear 2 (2.4) – 5 (2.7) 7 (1.9)
Fairly clear 46 (54.8) 31 (29.3) 62 (33.0) 139 (36.8)
Very clear 36 (42.9) 75 (70.8) 121 (64.4) 232 (61.4) < 0.001
Physician
No 5 (12.5) 8 (12.7) 19 (20.7) 32 (16.4)
Yes 35 (87.5) 55 (87.3) 73 (79.4) 163 (83.6) 0.32
How would you rate the information received?
Unclear 5 (11.4) – 5 (6.3) 10 (5.3)
Fairly clear 23 (52.3) 25 (38.5) 35 (44.3) 83 (44.2)
Very clear 16 (36.4) 40 (61.5) 39 (49.4) 95 (50.5) 0.03
Nurse/Biologist
No 9 (17.3) 7 (9.7) 13 (9.0) 29 (10.8)
Yes 43 (82.7) 65 (90.3) 131 (91.0) 239 (89.2) 0.24
How would you rate the information received?
Unclear – – 8 (5.7) 8 (3.2)
Fairly clear 22 (48.9) 24 (35.3) 42 (30.7) 89 (35.2)
Very clear 23 (51.1) 44 (64.7) 89 (63.6) 156 (61.7) 0.03
How would you rate the informed consent form?
Insufficiently understandable 2 (2.2) 1 (0.9) 6 (3.1) 9 (2.3)
Fairly understandable 59 (64.8) 61 (52.1) 95 (49.5) 215 (53.8)
Very understandable 30 (33.0) 55 (47.0) 91 (47.4) 176 (44.0) 0.10
Would you like to receive additional information
about the CRO-Biobank?
No 41 (46.6) 55 (48.7) 76 (39.8) 172 (43.9)
Yes 47 (53.4) 58 (51.3) 115 (60.2) 220 (56.1) 0.27
a Numbers do not add up to the total because of missing values.
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signing the informed consent form, this stage should
also involve truly educating patients so that they can
make informed decisions [1]. Despite growing interest in
patients’ understanding of research in which they are en-
rolled, participants’ awareness and attitudes towards bio-
logical material donated for research are not well-studied
[2]. Moreover, failing to properly inform patients about
the purposes of human tissue sampling and use has
caused a reduction of public confidence in biobanks,
which can only be recovered by a transparency policy [26].
Issues raised in this investigation bear on both scientific
and ethical perspectives [27]; we aimed to improveunderstanding, awareness and involvement of CRO-
Biobank participants through a multisource information
approach.
As no standard methodology for evaluating the in-
formed consent process exists [28], we developed a self-
administered questionnaire to assess patients’ information
and satisfaction, and a final assessment test on the biobank
purposes.
A review by Flory et al. evaluated effects of different
interventions to improve participants’ understanding of
informed consent for research, including multimedia in-
terventions, enhanced consent forms, extended discus-
sion, and miscellaneous methods. The review showed
Table 4 Distribution of answers given by 430 patients to the questionnaire investigating their knowledge about










N (%) N (%) N (%) N (%)
Did you donate biological material to CRO-Biobank?
No 8 (8.5) 6 (4.8) 5 (2.5) 19 (4.6)
Yes 86 (91.5) 119 (95.2) 194 (97.5) 399 (95.5) 0.07
Do you know what is stored in a biobank?
Biological material 85 (96.6) 117 (100.0) 193 (99.5) 395 (99.0)
Clinical records/scientific books 3 (3.4) – 1 (0.5) 4 (1.0) 0.03
Do you know the end use of the CRO-Biobank material?
Cancer research and care 92 (100.0) 118 (100.0) 199 (99.5) 409 (99.8)
Informative/economic purpose – – 1 (0.5) 1 (0.2) 0.59
a The sum does not add up to the total because of missing values.
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prove participants’ understanding, especially for less-
educated patients. It appears that the only effective
source of information is a one-on-one session where a
study team member spends extra time explaining the
study to the participant [1]. Our multisource informa-
tion procedure included this type of approach among
others; we added the support of a biobank nurse or a
biologist to the physician to provide more explanation in
simple language, particularly for less educated patients
[15]. Most participants of this study were satisfied with
the quality of the information received during the enrol-
ment, as they rated each CRO-Biobank source of infor-
mation “very understandable” (brochure, physician,
nurse/biologist) or “fairly understandable” (enhanced in-
formed consent form), although 56.1% expressed the
wish for further information. Education level was associ-
ated with understanding: more educated participants
rated sources of information as more understandable.
This is in accordance with other studies [1]. Less-
educated participants might, nevertheless, be poorly
skilled in filling in the questionnaire, which could lead
to underestimation of their understanding of the infor-
mation [1]. Another biobank set a multisource approach
to communication based on newsletters, external advis-
ory boards, and focus group discussions in order to
provide on-going feedback [10]. Participants expressed
their desire to be informed only about changes in pro-
tocols or informed consent procedures; this result em-
phasizes the need for constant communication on these
topics to maintain participants’ understanding, confi-
dence, and trust.
Our study gave us insight into patients’ knowledge of
biobanks prior to their participation therein. Only 36.5%
were aware of the existence of biobanks: this percentagedropped to 25.8% in less-educated patients. Most partici-
pants who knew of biobanks before entering the study
had found information through our Institute, which led
to an overestimation of the percentage. Indeed, our goal
of improving patients’ knowledge is not limited to the
present study but is part of our biobank policy. The in-
formational material can be found in various places
around the Institute (i.e., display cases, stands), on-line,
and through a dedicated phone line. The results of the
study indicate that our efforts were successful for 30.7%
of our patients (compared to 4.7% who answered that
they had been informed by other hospitals). The informa-
tion provided by our Institute was more effective than
television (21.3%), which is the main source of informa-
tion for less educated patients, and newspapers/magazines
(17.6%), or the Internet (6.6%).
The most noteworthy result was that, with our multi-
source information approach, more than 99% of partici-
pants correctly answered questions about the purposes
of biobanks. Moreover, our results showed that, unlike
most studies, our approach allowed the information to
be widely understood by less educated participants [1].
A survey among participants in another biobank, like
ours, indicated that participants were motivated by a
“pragmatic attitude” to contribute to research advance-
ments; knowing what prompts individuals to participate
helps define how to strengthen their involvement and
awareness.
A novel aspect of this study is to investigate how pa-
tients preferred to be informed. Most preferred multiple
sources of information. More educated patients preferred
a website, while less educated patients opted for having in-
formation provided by their general practitioner.
The study showed wide awareness among participants;
95.5% of patients were aware of their involvement in a
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to our biobank, the question: “Did you donate biological
material to CRO-Biobank?” was meant to see whether
they were aware of their participation). These data are in
accordance with studies by Toccaceli et al. (89.9%) [2]
and Nakayama et al. (92%) [29], but in contrast to those
of Moutel et al. (0%) [15].
The protection of personal rights in biobanks is a topic
of great interest [30,31], and studies of public perception
of biobanks have increased [30,32,33]. In contrast, we in-
vestigated the participants’ perceptions of this topic, ra-
ther than public perception. More than 98% of patients
felt respected in their privacy and desires, and most
rated the enhanced informed consent forms as “fairly
understandable” to “very understandable”; these results
represent an important aspect of the quality of our sys-
tem and our intention to make patients feel part of the
research.
Cancer patients face their diseases in personal ways;
their views on participating in research or biobank pro-
jects vary, and can be different from the general popula-
tion. For this reason, we directly investigated their
understanding and awareness rather than perform a gen-
eral population survey. Such surveys among cancer pa-
tients remain scarce but some articles have been
published over the years [34-39]. In particular, Mancini
et al. assessed cancer patients’ understanding about a
biobanking informed consent process in the framework
of a routine “opt-in” scenario [37]. Their results showed
that 61.5% of patients who remembered giving consent
and 31.5% of patients who declared not to have given
consent, actually had given it. Moreover 41.3% of pa-
tients understood that consent implied giving access to
their medical data. Scarce consensus exist about cancer
patients’ reasons for participating in a biobank. In our
experience, patients mainly contribute to aid cancer re-
search (in accordance with the survey of Huber et al.)
[39] and secondarily, to support care or for moral obli-
gation; in other studies they contribute hoping for per-
sonal benefit [38,39], because of societal welfare or as an
act of benevolence [38].
Nowadays, the need to collect informed consent for
biobanking is somewhat controversial. Some authors
proposed “opt-out” [40] or “opt-out-plus” procedures
[36]. Whereas participants in opt-in procedures expli-
citly express their consent, in opt-out procedures, in-
action signifies consent, and participants must
affirmatively decline to take part, either orally or in writ-
ing. In some countries, such as Denmark, France and
Belgium, this option is considered a sufficient consent
modality for the use of residual tissue for research [40].
The surveys by Vermeulen et al. of cancer patients sup-
port adoption of opt-plus procedure, in which patients
are informed about the possibility to opt-out, bothverbally and by means of a leaflet [35,36]. In contrast,
when Mancini et al. questioned cancer patients about
their attitudes concerning informed consent, most felt
that biobank research should require patients’ signed
consent. Opting-in is the method suggested for includ-
ing people in clinical research [41]; in most countries, it
is the only allowed solution.
Regardless of the type of procedure that is chosen, the
concept of informed consent is based on respect for par-
ticipants’ autonomy and their right to control their med-
ical care and research participation. Our system fulfils
this condition from both ethical and legal points of view.
Although our informed consent procedure was
designed and developed in an institutional biobank, its
features can be easily implemented at low cost by other
institutions thanks to its simplicity, which represents its
major strength. Moreover it can be applied in several
fields, from clinical practice to research, to improve pa-
tients’ awareness and understanding of information rele-
vant to the informed consent process. Resources needed
to apply this system are the following: (a) an initial in-
vestment of time to enhance the informed consent form
(see Figure 1) and to format the graphic layout of the pa-
tient’s information sheet to create a brochure, a poster,
and a web page; (b) a meeting to train staff about the
project; and (c) involvement of a trained biologist/nurse
who can give participants further information in plain
language, and answer any of their questions, before the
collection of samples site or through a phone line (esti-
mated time ≤ 15 minutes for each participant). The last
is the only resource that could lead to sizeable financial
outlay— the cost of a nurse’s services if one is not
already available. For our program, a research nurse
(whose job was to collect samples and interview patients
for our biobank) was trained with no additional cost to
our institution.
Among the limitations of the study, we must consider
potential bias due to participants who did not return the
questionnaire, or who refused to answer some questions.
Although we do not have the detailed demographical
data regarding non-responders, the percentage of them
was approximately the same distributed by department,
pathology, sex and age. We assessed patients’ perception
of the quality of each source of information, but this par-
ameter does not indicate the real quality of the sources.
As a starting point for future investigations of this topic,
we suggest developing an assessment test to be given
after having informed patients through each source. Fur-
ther studies are also needed to determine whether, after
a longer period (e.g. one year), participants still retain
the disclosed information. The multisource information
approach could also be optimized, for example by verify-
ing which sources are the most efficient and excluding
the others. To enhance the understanding of less
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involving their general practitioners as a new source of
information, as this was frequently requested by patients
in the questionnaire.Conclusions
Our results showed information given to participants was
well understood, that almost all patients acknowledged
their awareness of their participation in CRO-Biobank,
and that they were highly motivated, which implies that
providing a well-informed consent process improves pa-
tient autonomy in conscious decision making. Our
multisource information approach could be an effective
and easy-to-apply model for others to consider in improv-
ing participants’ awareness and understanding of informa-
tion provided in the informed consent process. It could
also be a low-cost system if it is possible to involve a nurse
or a biologist already working in the Institution.Additional files
Additional file 1: “CRO-Biobank brochure for patients”. Informative
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